In 2021, in the midst of the Covid-19 pandemic, I had cytoreductive surgery and HIPEC at the Basingstoke and North Hampshire hospital.
Pseudomyxoma Survivor has received a number of inquiries as to whether people with a diagnosis of pseudomyxoma peritonei (PMP) or appendix cancer should have a COVID-19 vaccination.
The current climate has presented us with many issues and one of the greatest concerns is not many of us have visited a hospital for care during the COVID-19 pandemic.
Biweekly Update on PMP 3
We hope you’ve been keeping safe and healthy during lockdown. Lockdown has gone on for weeks but at least the sunshine here in the UK has made everything feel better.
Biweekly Insight on PMP 2
We hope you’ve been keeping well in lockdown. This is a difficult time for everyone, especially for those of us living with or affected by pseudomyxoma peritonei and other cancers of the appendix. Our online community and Buddies system continue to provide forums of support and understanding, and we hope to see everyone there.
Biweekly insight on PMP
Given the difficult situation we find ourselves in, we wanted to ensure that everyone in our community receives the extra support they need from us. That’s why we have decided to launch a new initiative to send you more regular updates on topics which you may find of interest.
A Joint message from the PMI and CPOC
Here at Pseudomyxoma Survivor, we are doing as much as we can to support us all in the current climate.
As patients ourselves, we were concerned that treatment and monitoring may be affected as our specialists are supporting COVID-19 patients.
EuroPMP International Workshop on pseudomyxoma peritonei
In December, Susan and Angela have been asked to present at the EuroPMP International Workshop on pseudomyxoma peritonei. It is a privilege to be asked to present to this network of experts from many fields, including surgeons, pathologists, oncologists, radiologists, molecular biologists, bioinformaticians and allied health care professionals of which Angela is a participant.